The clinical utility of QSM: disease diagnosis, medical management, and surgical planning

Quantitative susceptibility mapping (QSM) is an MR technique that depicts and quantifies magnetic susceptibility sources. Mapping iron, the dominant susceptibility source in the brain, has many important clinical applications. Herein, we review QSM applications in the diagnosis, medical management, and surgical treatment of disease. To assist in early disease diagnosis, QSM can identify elevated iron levels in the motor cortex of amyotrophic lateral sclerosis patients, in the substantia nigra of Parkinson's disease (PD) patients, in the globus pallidus, putamen, and caudate of Huntington's disease patients, and in the basal ganglia of Wilson's disease patients. Additionally, QSM can distinguish between hemorrhage and calcification, which could prove useful in tumor subclassification, and can measure microbleeds in traumatic brain injury patients. In guiding medical management, QSM can be used to monitor iron chelation therapy in PD patients, to monitor smoldering inflammation of multiple sclerosis (MS) lesions after the blood–brain barrier (BBB) seals, to monitor active inflammation of MS lesions before the BBB seals without using gadolinium, and to monitor hematoma volume in intracerebral hemorrhage. QSM can also guide neurosurgical treatment. Neurosurgeons require accurate depiction of the subthalamic nucleus, a tiny deep gray matter nucleus, prior to inserting deep brain stimulation electrodes into the brains of PD patients. QSM is arguably the best imaging tool for depiction of the subthalamic nucleus. Finally, we discuss future directions, including bone QSM, cardiac QSM, and using QSM to map cerebral metabolic rate of oxygen. Copyright © 2016 John Wiley & Sons, Ltd.

[1]  Pascal Spincemaille,et al.  Quantitative mapping of cerebral metabolic rate of oxygen (CMRO2) using quantitative susceptibility mapping (QSM) , 2015, Magnetic resonance in medicine.

[2]  C. Lind,et al.  Magnetic resonance imaging of the subthalamic nucleus for deep brain stimulation. , 2016, Journal of neurosurgery.

[3]  Jon Thacker,et al.  Evaluation of Iron Content in Human Cerebral Cavernous Malformation Using Quantitative Susceptibility Mapping , 2014, Investigative radiology.

[4]  Rolf Gruetter,et al.  A modulated closed form solution for quantitative susceptibility mapping — A thorough evaluation and comparison to iterative methods based on edge prior knowledge , 2015, NeuroImage.

[5]  Yi Wang,et al.  Morphology enabled dipole inversion for quantitative susceptibility mapping using structural consistency between the magnitude image and the susceptibility map , 2012, NeuroImage.

[6]  Tsutomu Okada,et al.  Quantitative Susceptibility Mapping at 3 T and 1.5 T: Evaluation of Consistency and Reproducibility , 2015, Investigative radiology.

[7]  Weiyu Xu,et al.  Accuracy of the Morphology Enabled Dipole Inversion (MEDI) Algorithm for Quantitative Susceptibility Mapping in MRI , 2012, IEEE Transactions on Medical Imaging.

[8]  J. Reichenbach,et al.  Detection of Cerebral Microbleeds with Quantitative Susceptibility Mapping in the Arcabeta Mouse Model of Cerebral Amyloidosis , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  Tian Liu,et al.  Quantitative susceptibility mapping in patients with systemic lupus erythematosus: detection of abnormalities in normal-appearing basal ganglia , 2016, European Radiology.

[10]  S. Lehéricy,et al.  Reproducibility of R2* and quantitative susceptibility mapping (QSM) reconstruction methods in the basal ganglia of healthy subjects , 2017, NMR in biomedicine.

[11]  Ferdinand Schweser,et al.  Quantitative Susceptibility Mapping Differentiates between Blood Depositions and Calcifications in Patients with Glioblastoma , 2013, PloS one.

[12]  J. Dankert,et al.  PENICILLIN-SENSITIVE STREPTOCOCCAL ENDOCARDITIS , 1982, The Lancet.

[13]  D. Dexter,et al.  Brain iron metabolism and its perturbation in neurological diseases , 2011 .

[14]  A. Wilman,et al.  Background field removal using spherical mean value filtering and Tikhonov regularization , 2014, Magnetic resonance in medicine.

[15]  Paul Krack,et al.  Electrophysiological mapping for the implantation of deep brain stimulators for Parkinson's disease and tremor , 2006, Movement disorders : official journal of the Movement Disorder Society.

[16]  Erika P. Raven,et al.  Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging. , 2013, Journal of Alzheimer's disease : JAD.

[17]  Guy B. Williams,et al.  In Vivo Quantitative Susceptibility Mapping (QSM) in Alzheimer's Disease , 2013, PloS one.

[18]  Dong Zhou,et al.  Magnetic susceptibility anisotropy: Cylindrical symmetry from macroscopically ordered anisotropic molecules and accuracy of MRI measurements using few orientations , 2013, NeuroImage.

[19]  H. Lassmann,et al.  Pathology of multiple sclerosis and related inflammatory demyelinating diseases. , 2014, Handbook of clinical neurology.

[20]  Dong Zhou,et al.  An iterative spherical mean value method for background field removal in MRI , 2014, Magnetic resonance in medicine.

[21]  Tian Liu,et al.  Quantitative susceptibility mapping of the motor cortex in amyotrophic lateral sclerosis and primary lateral sclerosis. , 2015, AJR. American journal of roentgenology.

[22]  Yi Wang,et al.  Quantitative susceptibility mapping (QSM) of white matter multiple sclerosis lesions: Interpreting positive susceptibility and the presence of iron , 2015, Magnetic resonance in medicine.

[23]  Julie C Stout,et al.  Iron accumulation in the basal ganglia in Huntington's disease: cross-sectional data from the IMAGE-HD study , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[24]  R R Edelman,et al.  Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations , 2016, American Journal of Neuroradiology.

[25]  J. Ellis Cholinesterase Inhibitors in the Treatment of Dementia , 2005, The Journal of the American Osteopathic Association.

[26]  P. Jezzard,et al.  Quantitative measurement of cerebral physiology using respiratory-calibrated MRI , 2012, NeuroImage.

[27]  B. Forstmann,et al.  A gradual increase of iron toward the medial‐inferior tip of the subthalamic nucleus , 2014, Human brain mapping.

[28]  Patrik Brundin,et al.  Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. , 2002, Nature reviews. Neuroscience.

[29]  Xuemei Huang,et al.  Quantitative susceptibility mapping of the midbrain in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[30]  David Pitt,et al.  Iron Is a Sensitive Biomarker for Inflammation in Multiple Sclerosis Lesions , 2013, PloS one.

[31]  B. Rutt,et al.  In Vivo 7T MR Quantitative Susceptibility Mapping Reveals Opposite Susceptibility Contrast between Cortical and White Matter Lesions in Multiple Sclerosis , 2016, American Journal of Neuroradiology.

[32]  Wei Cao,et al.  A method for estimating and removing streaking artifacts in quantitative susceptibility mapping , 2015, NeuroImage.

[33]  Yi Wang,et al.  Magnetic source MRI: A new quantitative imaging of magnetic biomarkers , 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[34]  W. Frey,et al.  Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation , 2015, Neuroscience Letters.

[35]  Alzheimer’s Disease Neuroimaging Initiative,et al.  Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE , 2015 .

[36]  Pascal Spincemaille,et al.  Flow compensated quantitative susceptibility mapping for venous oxygenation imaging , 2014, Magnetic resonance in medicine.

[37]  H. Lassmann Pathophysiology of inflammation and tissue injury in multiple sclerosis: What are the targets for therapy , 2011, Journal of the Neurological Sciences.

[38]  Xue Xiao,et al.  Integrated Laplacian‐based phase unwrapping and background phase removal for quantitative susceptibility mapping , 2014, NMR in biomedicine.

[39]  Robert Turner,et al.  Seven-Tesla Magnetic Resonance Imaging in Wilson Disease Using Quantitative Susceptibility Mapping for Measurement of Copper Accumulation , 2014, Investigative radiology.

[40]  Tian Liu,et al.  Dynamic Permeability and Quantitative Susceptibility: Related Imaging Biomarkers in Cerebral Cavernous Malformations , 2014, Stroke.

[41]  Erich O. Richter,et al.  Determining the position and size of the subthalamic nucleus based on magnetic resonance imaging results in patients with advanced Parkinson disease. , 2004, Journal of neurosurgery.

[42]  Yi Wang,et al.  Improved subthalamic nucleus depiction with quantitative susceptibility mapping. , 2013, Radiology.

[43]  Yi Wang,et al.  Unambiguous identification of superparamagnetic iron oxide particles through quantitative susceptibility mapping of the nonlinear response to magnetic fields. , 2010, Magnetic resonance imaging.

[44]  Felix W. Wehrli,et al.  Susceptibility‐based time‐resolved whole‐organ and regional tissue oximetry , 2017, NMR in biomedicine.

[45]  Yi Wang,et al.  Background field removal by solving the Laplacian boundary value problem , 2014, NMR in biomedicine.

[46]  Scott Daniel Eggers Harrison's Neurology in Clinical Medicine , 2006 .

[47]  Yi Wang,et al.  Multiple sclerosis lesion geometry in quantitative susceptibility mapping (QSM) and phase imaging , 2015, Journal of magnetic resonance imaging : JMRI.

[48]  Claudine Joëlle Gauthier,et al.  Magnetic resonance imaging of resting OEF and CMRO2 using a generalized calibration model for hypercapnia and hyperoxia , 2012, NeuroImage.

[49]  Pascal Spincemaille,et al.  Reproducibility of quantitative susceptibility mapping in the brain at two field strengths from two vendors , 2015, Journal of magnetic resonance imaging : JMRI.

[50]  E Mark Haacke,et al.  Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2. , 2015, Magnetic resonance imaging.

[51]  C. Crainiceanu,et al.  Predicting Breakdown of the Blood-Brain Barrier in Multiple Sclerosis without Contrast Agents , 2012, American Journal of Neuroradiology.

[52]  Kristian Bredies,et al.  Fast quantitative susceptibility mapping using 3D EPI and total generalized variation , 2015, NeuroImage.

[53]  M V Knopp,et al.  Basal Ganglia Iron in Patients with Multiple Sclerosis Measured with 7T Quantitative Susceptibility Mapping Correlates with Inhibitory Control , 2016, American Journal of Neuroradiology.

[54]  R. Bowtell,et al.  Susceptibility mapping in the human brain using threshold‐based k‐space division , 2010, Magnetic resonance in medicine.

[55]  R. Grossman,et al.  Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging , 2009, Journal of magnetic resonance imaging : JMRI.

[56]  Shigeru Furui,et al.  High Signal Intensity in Dentate Nucleus on Unenhanced T1-weighted MR Images: Association with Linear versus Macrocyclic Gadolinium Chelate Administration. , 2015, Radiology.

[57]  Wei Li,et al.  Susceptibility tensor imaging (STI) of the brain , 2017, NMR in biomedicine.

[58]  A. Roebroeck,et al.  Ultra-high field magnetic resonance imaging of the basal ganglia and related structures , 2014, Front. Hum. Neurosci..

[59]  Pascal J. Kieslich,et al.  Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. , 2015, Radiology.

[60]  DuhamelAlain,et al.  Targeting chelatable iron as a therapeutic modality in Parkinson's disease. , 2014 .

[61]  Tian Liu,et al.  Intracranial calcifications and hemorrhages: characterization with quantitative susceptibility mapping. , 2013, Radiology.

[62]  J. Walshe,et al.  Chelation treatment of neurological Wilson's disease. , 1993, The Quarterly journal of medicine.

[63]  C. Marsden,et al.  Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia , 1992 .

[64]  B. Caffo,et al.  Lesion Heterogeneity on High-Field Susceptibility MRI Is Associated with Multiple Sclerosis Severity , 2016, American Journal of Neuroradiology.

[65]  H. Kamel,et al.  Oxygen Extraction Fraction and Stroke Risk in Patients with Carotid Stenosis or Occlusion: A Systematic Review and Meta-Analysis , 2014, American Journal of Neuroradiology.

[66]  Tian Liu,et al.  Enhancing k‐space quantitative susceptibility mapping by enforcing consistency on the cone data (CCD) with structural priors , 2016, Magnetic resonance in medicine.

[67]  Bing Wu,et al.  Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition , 2011, NeuroImage.

[68]  Y Wang,et al.  Quantitative Susceptibility Mapping and R2* Measured Changes during White Matter Lesion Development in Multiple Sclerosis: Myelin Breakdown, Myelin Debris Degradation and Removal, and Iron Accumulation , 2016, American Journal of Neuroradiology.

[69]  C. Marsden,et al.  INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN , 1987, The Lancet.

[70]  Pascal Spincemaille,et al.  Cerebral microbleeds: burden assessment by using quantitative susceptibility mapping. , 2012, Radiology.

[71]  G. Johnson,et al.  Dynamic contrast-enhanced quantitative susceptibility mapping with ultrashort echo time MRI for evaluating renal function. , 2016, American journal of physiology. Renal physiology.

[72]  Lawrence L. Wald,et al.  Fast quantitative susceptibility mapping with L1‐regularization and automatic parameter selection , 2013, Magnetic resonance in medicine.

[73]  M. Yorubulut,et al.  T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores. , 2004, Neurology India.

[74]  Jian-Qiang Lu,et al.  Validation of quantitative susceptibility mapping with Perls' iron staining for subcortical gray matter , 2015, NeuroImage.

[75]  Ravi S. Menon,et al.  Multiple sclerosis: improved identification of disease-relevant changes in gray and white matter by using susceptibility-based MR imaging. , 2014, Radiology.

[76]  J. Duyn,et al.  Magnetic susceptibility mapping of brain tissue in vivo using MRI phase data , 2009, Magnetic resonance in medicine.

[77]  P. McCrory,et al.  Updated guidelines for the management of sports-related concussion in general practice. , 2014, Australian family physician.

[78]  E M Haacke,et al.  Iron and Non-Iron-Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRI , 2016, American Journal of Neuroradiology.

[79]  Ferdinand Schweser,et al.  Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study , 2012, NeuroImage.

[80]  Y Wang,et al.  Usefulness of Quantitative Susceptibility Mapping for the Diagnosis of Parkinson Disease , 2015, American Journal of Neuroradiology.

[81]  J. Schenck,et al.  Iron accumulation in the substantia nigra of patients with Alzheimer disease and parkinsonism. , 2009, Archives of neurology.

[82]  Jiwon Oh,et al.  Magnetic susceptibility contrast variations in multiple sclerosis lesions , 2016, Journal of magnetic resonance imaging : JMRI.

[83]  Richard D Moore,et al.  Performance of a Limiting-Antigen Avidity Enzyme Immunoassay for Cross-Sectional Estimation of HIV Incidence in the United States , 2013, PloS one.

[84]  Y. Cheng,et al.  Susceptibility mapping as a means to visualize veins and quantify oxygen saturation , 2010, Journal of magnetic resonance imaging : JMRI.

[85]  P-Y Lin,et al.  Quantitative Susceptibility Mapping of Human Brain at 3T: A Multisite Reproducibility Study , 2015, American Journal of Neuroradiology.

[86]  P. Lundberg,et al.  Quantitative MRI for Analysis of Active Multiple Sclerosis Lesions without Gadolinium-Based Contrast Agent , 2016, American Journal of Neuroradiology.

[87]  Nian Wang,et al.  Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping , 2017, NMR in biomedicine.

[88]  V. Caso,et al.  Neuroimaging in Intracerebral Hemorrhage , 2014, Stroke.

[89]  Tian Liu,et al.  Internal structures of the globus pallidus in patients with Parkinson’s disease: evaluation with quantitative susceptibility mapping (QSM) , 2015, European Radiology.

[90]  Wei Liu,et al.  Imaging Cerebral Microhemorrhages in Military Service Members with Chronic Traumatic Brain Injury. , 2016, Radiology.

[91]  D. Kansagara,et al.  Complications of Mild Traumatic Brain Injury in Veterans and Military Personnel: A Systematic Review , 2013 .

[92]  R. Spataro,et al.  Factors affecting the diagnostic delay in amyotrophic lateral sclerosis , 2012, Clinical Neurology and Neurosurgery.

[93]  F. Barkhof,et al.  Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. , 1998, Brain : a journal of neurology.

[94]  Robert Zivadinov,et al.  Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis A case-control study , 2012, NeuroImage.

[95]  T. Duong,et al.  Amethod for estimating and removing streaking artifacts in quantitative susceptibility mapping , 2015 .

[96]  Shuai Wang,et al.  Noise Effects in Various Quantitative Susceptibility Mapping Methods , 2013, IEEE Transactions on Biomedical Engineering.

[97]  Y Wang,et al.  Lateral Asymmetry and Spatial Difference of Iron Deposition in the Substantia Nigra of Patients with Parkinson Disease Measured with Quantitative Susceptibility Mapping , 2016, American Journal of Neuroradiology.

[98]  Yi Wang,et al.  Quantitative s usceptibility Mapping of Multiple s clerosis lesions at Various ages 1 , 2014 .

[99]  Pascal Spincemaille,et al.  The influence of molecular order and microstructure on the R2* and the magnetic susceptibility tensor. , 2016, Magnetic resonance imaging.

[100]  Paul S Larson,et al.  Image-guided deep brain stimulation. , 2014, Neurosurgery clinics of North America.

[101]  Min Zhang,et al.  Reducing the object orientation dependence of susceptibility effects in gradient echo MRI through quantitative susceptibility mapping , 2012, Magnetic resonance in medicine.

[102]  Jeff H Duyn,et al.  The role of iron in brain ageing and neurodegenerative disorders , 2014, The Lancet Neurology.

[103]  M. Dwyer,et al.  Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing–remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly , 2015, Journal of Neuroimmunology.

[104]  Yi Wang,et al.  Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker , 2014, Magnetic resonance in medicine.

[105]  Pascal Spincemaille,et al.  Nonlinear Regularization for Per Voxel Estimation of Magnetic Susceptibility Distributions From MRI Field Maps , 2010, IEEE Transactions on Medical Imaging.

[106]  Jeff H. Duyn,et al.  Iron Accumulation in Deep Cortical Layers Accounts for MRI Signal Abnormalities in ALS: Correlating 7 Tesla MRI and Pathology , 2012, PloS one.

[107]  Bruce R. Rosen,et al.  Regional quantification of cerebral venous oxygenation from MRI susceptibility during hypercapnia , 2015, NeuroImage.

[108]  J. Connor,et al.  Iron status and neural functioning. , 2003, Annual review of nutrition.

[109]  Yi Wang,et al.  Morphology enabled dipole inversion (MEDI) from a single‐angle acquisition: Comparison with COSMOS in human brain imaging , 2011, Magnetic resonance in medicine.

[110]  Chunlei Liu Susceptibility tensor imaging , 2010, Magnetic resonance in medicine.

[111]  Yi Wang,et al.  Quantitative susceptibility map reconstruction from MR phase data using bayesian regularization: Validation and application to brain imaging , 2010, Magnetic resonance in medicine.

[112]  Christian Langkammer,et al.  Iron and Neurodegeneration in Multiple Sclerosis , 2011, Multiple sclerosis international.

[113]  Pascal Spincemaille,et al.  Nonlinear formulation of the magnetic field to source relationship for robust quantitative susceptibility mapping , 2013, Magnetic resonance in medicine.

[114]  T. Rouault,et al.  Iron metabolism in the CNS: implications for neurodegenerative diseases , 2013, Nature Reviews Neuroscience.

[115]  Simon Hametner,et al.  Iron and neurodegeneration in the multiple sclerosis brain , 2013, Annals of neurology.

[116]  R. Bowtell,et al.  Increase in the iron content of the substantia nigra and red nucleus in multiple sclerosis and clinically isolated syndrome: A 7 Tesla MRI study , 2015, Journal of magnetic resonance imaging : JMRI.

[117]  B. Forstmann,et al.  Direct visualization of the subthalamic nucleus and its iron distribution using high‐resolution susceptibility mapping , 2012, Human brain mapping.

[118]  Yi Wang,et al.  Calculation of susceptibility through multiple orientation sampling (COSMOS): A method for conditioning the inverse problem from measured magnetic field map to susceptibility source image in MRI , 2009, Magnetic resonance in medicine.

[119]  Min Lou,et al.  Hematoma Volume Measurement in Gradient Echo MRI Using Quantitative Susceptibility Mapping , 2013, Stroke.

[120]  Xu Li,et al.  Mapping magnetic susceptibility anisotropies of white matter in vivo in the human brain at 7T , 2012, NeuroImage.

[121]  Yi Wang,et al.  Quantitative MR susceptibility mapping using piece‐wise constant regularized inversion of the magnetic field , 2008, Magnetic resonance in medicine.

[122]  Tian Liu,et al.  Oxygen extraction fraction measurement using quantitative susceptibility mapping: Comparison with positron emission tomography , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[123]  J. Reichenbach,et al.  Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. , 2010, Medical physics.

[124]  Luca Roccatagliata,et al.  Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype. , 2009, Radiology.

[125]  J. Broderick,et al.  Volume of Intracerebral Hemorrhage: A Powerful and Easy‐to‐Use Predictor of 30‐Day Mortality , 1993, Stroke.

[126]  B. Hallgren,et al.  THE EFFECT OF AGE ON THE NON‐HAEMIN IRON IN THE HUMAN BRAIN , 1958, Journal of neurochemistry.

[127]  Himanshu Bhat,et al.  Quantitative oxygenation venography from MRI phase , 2014, Magnetic resonance in medicine.

[128]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[129]  C. A. Treaba,et al.  Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity? , 2014, Diagnostic and interventional radiology.

[130]  Tao Wang,et al.  Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease , 2013, Neurobiology of Aging.

[131]  P. V. van Zijl,et al.  Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease , 2016, American Journal of Neuroradiology.

[132]  J Tang,et al.  Improving susceptibility mapping using a threshold‐based K‐space/image domain iterative reconstruction approach , 2013, Magnetic resonance in medicine.

[133]  Margit Jehna,et al.  Quantitative susceptibility mapping in multiple sclerosis. , 2013, Radiology.

[134]  Won-Jin Moon,et al.  Patterns of Brain Iron Accumulation in Vascular Dementia and Alzheimer's Dementia Using Quantitative Susceptibility Mapping Imaging. , 2016, Journal of Alzheimer's disease : JAD.

[135]  Martin Styner,et al.  Combined R2* and Diffusion Tensor Imaging Changes in the Substantia Nigra in Parkinson's Disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[136]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.

[137]  Y Wang,et al.  Magnetic Susceptibility from Quantitative Susceptibility Mapping Can Differentiate New Enhancing from Nonenhancing Multiple Sclerosis Lesions without Gadolinium Injection , 2016, American Journal of Neuroradiology.

[138]  E. Haacke,et al.  Quantitative susceptibility mapping: current status and future directions. , 2015, Magnetic resonance imaging.

[139]  Yan Zhang,et al.  Longitudinal change in magnetic susceptibility of new enhanced multiple sclerosis (MS) lesions measured on serial quantitative susceptibility mapping (QSM) , 2016, Journal of magnetic resonance imaging : JMRI.

[140]  Bing Wu,et al.  High-field (9.4T) MRI of brain dysmyelination by quantitative mapping of magnetic susceptibility , 2011, NeuroImage.

[141]  Reeti Tandon,et al.  High-field Magnetic Resonance Imaging of Brain Iron in Alzheimer Disease , 2006, Topics in magnetic resonance imaging : TMRI.

[142]  Keith A. Johnson,et al.  Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE , 2015, Nature Communications.

[143]  Ferdinand Schweser,et al.  Quantitative imaging of intrinsic magnetic tissue properties using MRI signal phase: An approach to in vivo brain iron metabolism? , 2011, NeuroImage.

[144]  Yi Wang,et al.  Iron in Multiple Sclerosis and Its Noninvasive Imaging with Quantitative Susceptibility Mapping , 2016, International journal of molecular sciences.

[145]  Chung-Ping Lo,et al.  Comparison of diffusion-weighted imaging and contrast-enhanced T1-weighted imaging on a single baseline MRI for demonstrating dissemination in time in multiple sclerosis , 2014, BMC Neurology.